Key result
Despite a growing population of individuals with single ventricle heart disease living with Fontan circulation, there are no specific treatments to maintain long-term myocardial performance.
Why the study?
There is little understanding of the underlying mechanisms of heart failure, arrhythmias, pulmonary and lymphatic vascular abnormalities, and other morbidities in single ventricle heart disease, leaving no specific treatments to maintain long-term myocardial performance or optimize outcomes.
Highlights the growing population of single ventricle patients and the critical need for research into underlying mechanisms and specific treatments to improve long-term outcomes.
Abstracts Because of remarkable advances in survival over the past 40 years, the worldwide population of individuals with single ventricle heart disease living with Fontan circulation has grown to ≈70 000, with nearly half aged >18 years. Survival to at least 30 years of age is now achievable for 75% of Fontan patients. On the other hand, single ventricle patients account for the largest group of the 6000 to 8000 children hospitalized with circulation failure, with or without heart failure annually in the United States, with the highest in-hospital mortality. Because there is little understanding of the underlying mechanisms of heart failure, arrhythmias, pulmonary and lymphatic vascular abnormalities, and other morbidities, there are no specific treatments to maintain long-term myocardial performance or to optimize overall patient outcomes.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2020) studied Single ventricle heart disease with Fontan circulation. Despite a growing population of individuals with single ventricle heart disease living with Fontan circulation, there are no specific treatments to maintain long-term myocardial performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: